The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity
Open accessAbstract
Mitochondrial disorders represent a large collection of rare syndromes that are difficult to manage both because we do not fully understand biochemical pathogenesis and because we currently lack facile markers of severity. The m.3243A>G variant is the most common heteroplasmic mitochondrial DNA mutation and underlies a spectrum of diseases, notably mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS). To identify robust circulating markers of m.3243A>G disease, we first performed discovery proteomics, targeted metabolomics, and untargeted metabolomics on plasma from a deeply phenotyped cohort (102 patients, 32 controls). In a validation phase, we measured concentrations of prioritized metabolites in an independent cohort using distinct methods. We validated 20 analytes (1 protein, 19 metabolites) that distinguish patients with MELAS from controls. The collection includes classic (lactate, alanine) and more recently identified (GDF-15, α-hydroxybutyrate) mitochondrial markers. By mining untargeted mass-spectra we uncovered 3 less well-studied metabolite families: N-lactoyl-amino acids, β-hydroxy acylcarnitines, and β-hydroxy fatty acids. Many of these 20 analytes correlate strongly with established measures of severity, including Karnofsky status, and mechanistically, nearly all markers are attributable to an elevated NADH/NAD+ ratio, or NADH-reductive stress. Our work defines a panel of organelle function tests related to NADH-reductive stress that should enable classification and monitoring of mitochondrial disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging
Kujoth, G. C., Hiona, A., Pugh, T. D., Someya, S., Panzer, K., Wohlgemuth, S. E., Hofer, T., Seo, A. Y., Sullivan, R., Jobling, W. A., et al. (2005) · Science · doi:10.1126/science.1112125 · Cited by 2,165
Goto, Y.-I., Nonaka, I., & Horai, S. (1990) · Nature · doi:10.1038/348651a0 · Cited by 2,070
Williamson, D., Lund, P., & Krebs, H. (1967) · Biochemical Journal · doi:10.1042/bj1030514 · Cited by 1,871
Plasma proteomic signature of age in healthy humans
Tanaka, T., Biancotto, A., Moaddel, R., Moore, A. Z., Gonzalez‐Freire, M., Aon, M. A., Candia, J., Zhang, P., Cheung, F., Fantoni, G., et al. (2018) · Aging Cell · doi:10.1111/acel.12799 · Cited by 562
Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis
Chung, H. K., Ryu, D., Kim, K. S., Chang, J. Y., Kim, Y. K., Yi, H.-S., Kang, S. G., Choi, M. J., Lee, S. E., Jung, S.-B., et al. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201607110 · Cited by 357
Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders
Yatsuga, S., Fujita, Y., Ishii, A., Fukumoto, Y., Arahata, H., Kakuma, T., Kojima, T., Ito, M., Tanaka, M., Saiki, R., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24506 · Cited by 293
Evaluation of 13C isotopic tracers for metabolic flux analysis in mammalian cells
Metallo, C. M., Walther, J. L., & Stephanopoulos, G. (2009) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.07.010 · Cited by 280 · cited 9×
“Hearing loss 16 (80)*** 31 (38)** 3 (9) number (%) Short statureH 3 (15)** 0 (0) 0 (0) number (%) Growth failureH 1 (5) 1 (1.”
BackgroundInfluentialDecrease of 3243 A–>G mtDNA mutation from blood in MELAS syndrome: a longitudinal study
Rahman, S., Poulton, J., Marchington, D., & Suomalainen, A. (2001) · The American Journal of Human Genetics · doi:10.1086/316930 · Cited by 237
Whole exome sequencing of suspected mitochondrial patients in clinical practice
Wortmann, S. B., Koolen, D. A., Smeitink, J. A., den van Heuvel, L., & Rodenburg, R. J. (2015) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-015-9823-y · Cited by 233
Tornberg, J., Sykiotis, G. P., Keefe, K., Plummer, L., Hoang, X., Hall, J. E., Quinton, R., Seminara, S. B., Hughes, V., Van Vliet, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102284108 · Cited by 177
Powering the Immune System: Mitochondria in Immune Function and Deficiency
Walker, M. A., Volpi, S., Sims, K. B., Walter, J. E., & Traggiai, E. (2014) · Journal of Immunology Research · doi:10.1155/2014/164309 · Cited by 83 · cited 1×
“Two clues regarding the potential role of immune dysregulation emerge from our measurements: patients with MELAS have a subclinical relative leukocytosis (Table 2), and sE-selectin, a soluble vascular endothelial adhesion molecule involved in leukocyte extravasation that correlates with sepsis severity, is markedly el…”
BackgroundSelf-citation
Cited by
Mitochondrial signal transduction
Picard, M., & Shirihai, O. S. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.008 · Cited by 638
An exercise-inducible metabolite that suppresses feeding and obesity
Li, V. L., He, Y., Contrepois, K., Liu, H., Kim, J. T., Wiggenhorn, A. L., Tanzo, J. T., Tung, A. S.-H., Lyu, X., Zushin, P.-J. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04828-5 · Cited by 331
Hypermetabolism and energetic constraints in mitochondrial disorders
Sercel, A. J., Sturm, G., Gallagher, D., St-Onge, M.-P., Kempes, C. P., Pontzer, H., Hirano, M., & Picard, M. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00968-8 · Cited by 34
Self-citation
Metadata
- Authors
- Sharma, R., Reinstadler, B., Engelstad, K., Skinner, O. S., Stackowitz, E., Haller, R. G., Clish, C. B., Pierce, K., Walker, M. A., Fryer, R., Oglesbee, D., Mao, X., Shungu, D. C., Khatri, A., Hirano, M., De Vivo, D. C., & Mootha, V. K.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-01-19
- Volume
- 131
- Issue
- 2
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3125364150
- Cited by
- 204
- References
- 11
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.